skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Refinado por: Base de dados/Biblioteca: ClinicalKey remover Nome da Publicação: Value In Health remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Development and Validation of a Microsimulation Economic Model to Evaluate the Disease Burden Associated with Smoking and the Cost-Effectiveness of Tobacco Control Interventions in Latin America
Development and Validation of a Microsimulation Economic Model to Evaluate the Disease Burden Associated with Smoking and the Cost-Effectiveness of Tobacco Control Interventions in Latin America
Material Type:
Artigo 		Adicionar ao Meu Espaço

Development and Validation of a Microsimulation Economic Model to Evaluate the Disease Burden Associated with Smoking and the Cost-Effectiveness of Tobacco Control Interventions in Latin America

Pichon-Riviere, Andres, MD, MSc, PhD ; Augustovski, Federico, MD, MSc ; Bardach, Ariel, MD, MSc ; Colantonio, Lisandro, MD, MSc

Value in health, 2011-07, Vol.14 (5), p.S51-S59 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por
2
POSC111 Cost-Minimization Analysis of Bovine and Porcine Bioprosthetic Aortic Valves for the Treatment of Severe Aortic Stenosis in Colombia
POSC111 Cost-Minimization Analysis of Bovine and Porcine Bioprosthetic Aortic Valves for the Treatment of Severe Aortic Stenosis in Colombia
Material Type:
Artigo 		Adicionar ao Meu Espaço

POSC111 Cost-Minimization Analysis of Bovine and Porcine Bioprosthetic Aortic Valves for the Treatment of Severe Aortic Stenosis in Colombia

Sanchez, L ; Dias Alves, MR

Value in health, 2022-01, Vol.25 (1), p.S108-S109 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
3
EE467 Estimation of Budget Impact With the Substitution of Biologic Reference Product for Biosimilars in Patients With Rheumatoid Arthritis From the Perspective of Medium Size Healthcare Insurance in Brazil
EE467 Estimation of Budget Impact With the Substitution of Biologic Reference Product for Biosimilars in Patients With Rheumatoid Arthritis From the Perspective of Medium Size Healthcare Insurance in Brazil
Material Type:
Artigo 		Adicionar ao Meu Espaço

EE467 Estimation of Budget Impact With the Substitution of Biologic Reference Product for Biosimilars in Patients With Rheumatoid Arthritis From the Perspective of Medium Size Healthcare Insurance in Brazil

Alves, Junior JM ; Prota, FE

Value in health, 2024-06, Vol.27 (6), p.S142-S142 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
4
PSS37 - A SYSTEMATIC REVIEW OF THE METHODOLOGICAL QUALITY OF ECONOMIC STUDIES EVALUATING OPHTHALMIC DRUGS
PSS37 - A SYSTEMATIC REVIEW OF THE METHODOLOGICAL QUALITY OF ECONOMIC STUDIES EVALUATING OPHTHALMIC DRUGS
Material Type:
Artigo 		Adicionar ao Meu Espaço

PSS37 - A SYSTEMATIC REVIEW OF THE METHODOLOGICAL QUALITY OF ECONOMIC STUDIES EVALUATING OPHTHALMIC DRUGS

Ribeiro, I. ; Batel Marques, F. ; Alves, D. ; Alves, C.

Value in health, 2018-10, Vol.21, p.S429-S429 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
5
MT76 DiMe Library of Digital Endpoints: Strengths, Weaknesses, and Pathways for Improvement in Digital Health Research
MT76 DiMe Library of Digital Endpoints: Strengths, Weaknesses, and Pathways for Improvement in Digital Health Research
Material Type:
Artigo 		Adicionar ao Meu Espaço

MT76 DiMe Library of Digital Endpoints: Strengths, Weaknesses, and Pathways for Improvement in Digital Health Research

Alves Favaro, M. ; De Giorgio, F. ; Brooks, T. ; Bothorel, S.

Value in health, 2023-12, Vol.26 (12), p.S441 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
6
HTA46 Relationship Between the Directness of the Evidence and Identification of Added Therapeutic Value: An Analysis of HTA Procedures
HTA46 Relationship Between the Directness of the Evidence and Identification of Added Therapeutic Value: An Analysis of HTA Procedures
Material Type:
Artigo 		Adicionar ao Meu Espaço

HTA46 Relationship Between the Directness of the Evidence and Identification of Added Therapeutic Value: An Analysis of HTA Procedures

Ribeiro, C. ; Penedones, A. ; Mendes, D. ; Alves, C.

Value in health, 2023-12, Vol.26 (12), p.S328-S329 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
7
HTA338 Characterization of the Evidence Supporting the Relative Effectiveness Evaluations in Health Technologies Assessment: A Review
HTA338 Characterization of the Evidence Supporting the Relative Effectiveness Evaluations in Health Technologies Assessment: A Review
Material Type:
Artigo 		Adicionar ao Meu Espaço

HTA338 Characterization of the Evidence Supporting the Relative Effectiveness Evaluations in Health Technologies Assessment: A Review

Ribeiro, C. ; Penedones, A. ; Mendes, D. ; Alves, C.

Value in health, 2023-12, Vol.26 (12), p.S385 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
8
SA59 Clinical Evidence on Acanthamoeba Keratitis Treatments: Systematic Literature Review
SA59 Clinical Evidence on Acanthamoeba Keratitis Treatments: Systematic Literature Review
Material Type:
Artigo 		Adicionar ao Meu Espaço

SA59 Clinical Evidence on Acanthamoeba Keratitis Treatments: Systematic Literature Review

Tofani, L. ; Bodicoat, D. ; Alves, A. ; Arteaga, A. ; Papa, V.

Value in health, 2023-12, Vol.26 (12), p.S552-S553 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
9
Cost-Utility Analysis of Natalizumab as First-Line Treatment of Highly-Active Relapsing-Remitting Multiple Sclerosis in the Brazilian Public Healthcare System
Cost-Utility Analysis of Natalizumab as First-Line Treatment of Highly-Active Relapsing-Remitting Multiple Sclerosis in the Brazilian Public Healthcare System
Material Type:
Artigo 		Adicionar ao Meu Espaço

Cost-Utility Analysis of Natalizumab as First-Line Treatment of Highly-Active Relapsing-Remitting Multiple Sclerosis in the Brazilian Public Healthcare System

Alves, J ; Machado, M

Value in health, 2015-11, Vol.18 (7), p.A878-A878 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por
10
PND6 - Cost-Utility Analysis of Natalizumab as First-Line Treatment of Highly-Active Relapsing-Remitting Multiple Sclerosis in the Brazilian Public Healthcare System
PND6 - Cost-Utility Analysis of Natalizumab as First-Line Treatment of Highly-Active Relapsing-Remitting Multiple Sclerosis in the Brazilian Public Healthcare System
Material Type:
Artigo 		Adicionar ao Meu Espaço

PND6 - Cost-Utility Analysis of Natalizumab as First-Line Treatment of Highly-Active Relapsing-Remitting Multiple Sclerosis in the Brazilian Public Healthcare System

Alves, J ; Machado, M

Value in health, 2015-11, Vol.18 (7), p.A878-A878 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.